The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

Pharmacogenomics Journal

Volumn 4, Issue 4, 2004, Pages 283-286

  Suzuki, Y ^a   Sawamura, K ^a   Someya, T ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

5 hydroxytryptamine 1A receptor; Clinical response; Depression; Fluvoxamine; Gene polymorphism

Indexed keywords

ASPARTIC ACID; FLUVOXAMINE; GLYCINE; SEROTONIN 1A RECEPTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASPARTIC ACID; DEPRESSIVE DISORDER; FEMALE; FLUVOXAMINE; GENOTYPE; GLYCINE; HUMANS; MALE; RECEPTOR, SEROTONIN, 5-HT1A; TREATMENT OUTCOME;

EID: 4344637548     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500256     Document Type: Article

References (20)

1. Judd LL. Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol 1995; 10(Suppl 4): 5-10.
2. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993; 150: 1447-1465.
3. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695-704.
4. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-226.
5. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7(Suppl): 24S-35S.
6. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9(Suppl 1): 19-26.
7. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
8. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-383.
9. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333: 342-348.
10. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243-245.
11. Fuller RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163-167.
12. Rutter JJ, Gundlah C, Auerbach SB. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994; 171: 183-186.
13. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998; 155: 1346-1351.
14. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001; 21: 36-45.
15. Nakhai B, Nielsen DA, Linnoila M, Goldman D. Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun 1995; 210: 530-536.
16. Erdmann J, Shimron-Abarbanell D, Cichon S, Albus M, Maier W, Lichtermann D et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene. Am J Med Genet 1995; 60: 393-399.
17. Kawanishi Y, Harada S, Tachikawa H, Okubo T, Shiraishi H. Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am J Med Genet 1998; 81: 434-439.
18. Nishiguchi N, Shirakawa O, Ono H, Nishimura A, Nushida H, Ueno Y et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet 2002; 114: 423-425.
19. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81-89.
20. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-1597.